type of digital currency See results about

As an economic and financial center, Shanghai has outstanding advantages in integrated circuits, biomedicine and new materials. The introduction of this merger and reorganization plan highlights Shanghai's determination to actively develop new quality productive forces and achieve autonomy and control.From the perspective of institutional attention, Zhongwei Company and Weir Co., Ltd. have more than 30 institutional ratings, while Hengxuan Technology, Lanqi Technology, UIH Medical and Microelectrophysiology -U have more than 20 institutional ratings.Judging from the market performance, the average growth rate of 41 key sector stocks since September 18 is close to 56%, far outperforming the performance of the broader market in the same period. Among them, two stocks of Xinxiangwei and SMIC doubled. Xinxiangwei's main business focuses on the research, development, design and sales of display chips, and is committed to providing complete display chip system solutions.

According to the key industrial fields mentioned in the action plan, Shanghai's local semiconductor leading enterprises, pharmaceutical leading enterprises and new material leading enterprises are also expected to benefit from the merger and acquisition plan.Many stocks have doubled.After-hours big profits are related to mergers and acquisitions, restructuring, Shanghai state-owned shares have these.

According to data treasure statistics, excluding central enterprises and state-owned enterprises, among the above three sectors, there are 41 Shanghai local stocks with a market value exceeding 10 billion yuan.Since the beginning of this year, favorable policies for mergers and acquisitions have been frequent. Since the CSRC issued the Opinions on Deepening the Market Reform of Listed Companies' M&A and Restructuring on September 24th, the support of all parties to the M&A and restructuring market has continued to increase, and the M&A and restructuring market has continued to be active.The stagflation stocks mainly include Haohaishengke, Shanghai Laishi and Weir. Among them, Haohai Shengke increased by less than 10%. The company is a scientific and technological innovative enterprise that applies biomedical materials technology and genetic engineering technology to research, develop, produce and sell medical devices and drugs. It is committed to providing innovative medical products for the market through technological innovation and transformation, integration of domestic and foreign resources and large-scale production, and gradually realizing the import substitution of related medical products, thus becoming a leading enterprise in the field of biomedical materials.